Small molecule · developed by Viking Therapeutics
VK5211 is a selective androgen receptor agonist studied for hip fracture recovery. It is designed to promote muscle protein synthesis and bone formation to accelerate healing and restore function in patients with hip fractures.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02578095 | Phase 2 | Hip Fractures | Completed | VKTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hip Fractures
See VKTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VKTX catalysts and pipeline →